| Mycosis Fungoides
Valchlor vs Poteligeo
Side-by-side clinical, coverage, and cost comparison for mycosis fungoides.Deep comparison between: Valchlor vs Poteligeo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsPoteligeo has a higher rate of injection site reactions vs Valchlor based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Poteligeo but not Valchlor, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Valchlor
Poteligeo
At A Glance
Topical
Once daily
Alkylating agent
IV infusion
Every 1-2 weeks
CCR4 antagonist
Indications
- Mycosis Fungoides
- Mycosis Fungoides
- Sezary Syndrome
Dosing
Mycosis Fungoides Apply a thin film once daily to completely dry skin at least 4 hours before or 30 minutes after showering; stop for skin ulceration, blistering, or moderately-severe/severe dermatitis and restart at reduced frequency (once every 3 days) upon improvement, advancing to every other day then once daily if tolerated.
Mycosis Fungoides, Sezary Syndrome 1 mg/kg IV infusion over at least 60 minutes on days 1, 8, 15, and 22 of the first 28-day cycle, then on days 1 and 15 of each subsequent 28-day cycle until disease progression or unacceptable toxicity.
Contraindications
- Known severe hypersensitivity to mechlorethamine, including anaphylaxis
—
Adverse Reactions
Most common (>=5%) Dermatitis, pruritus, bacterial skin infection, skin ulceration or blistering, skin hyperpigmentation
Serious Mucosal or eye injury, non-melanoma skin cancer, secondary exposure to caregivers
Most common (>=20%) Rash/drug eruption, infusion related reactions, fatigue, diarrhea, upper respiratory tract infection, musculoskeletal pain
Serious Pneumonia, sepsis, pyrexia, skin infection, hepatitis, pneumonitis, infusion related reaction, lower respiratory tract infection, renal insufficiency
Postmarketing Immune-mediated colitis, hepatitis B virus reactivation, stress cardiomyopathy, granuloma
Pharmacology
Mechlorethamine (nitrogen mustard) is an alkylating agent that inhibits rapidly proliferating cells; systemic exposure is undetectable after topical administration.
Mogamulizumab-kpkc is a defucosylated, humanized IgG1 kappa monoclonal antibody that binds to CCR4 and depletes CCR4-expressing T-cell malignancy cells, regulatory T-cells, and Th2 T-cell subsets via antibody-dependent cellular cytotoxicity (ADCC).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Valchlor
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
Poteligeo
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Valchlor
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (3/8)
Poteligeo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Valchlor
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Poteligeo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableGood Days: Hodgkin's Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ValchlorView full Valchlor profile
PoteligeoView full Poteligeo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.